Summary
Claims pertain to pricing, savings programs, and insurance coverage which are not described in FDA-approved labeling for Fiasp. All provided claims are unsupported by the label.
Category Scores
Accurate Statements
Unsupported Statements
The price of Fiasp can vary.
Not in labeling: pricing or MSRP information is not included in FDA-approved labeling for Fiasp.
A 10-count box of Fiasp PenFill cartridges (3 mL each) has been listed at approximately $439.99 without insurance.
Not in labeling: pricing or MSRP information is not included in FDA-approved labeling for Fiasp.
The cost of Fiasp can be influenced by the dosage.
Not in labeling: pricing details related to dosage are not covered in FDA-approved labeling.
The cost of Fiasp can be influenced by the quantity purchased.
Not in labeling: quantity-based pricing information is not part of FDA-approved labeling.
The cost of Fiasp can be influenced by insurance coverage.
Not in labeling: insurance coverage or pricing impact details are not included in FDA-approved labeling.
Insurance plans may offer coverage for Fiasp.
Not in labeling: statements about insurance plan coverage are not part of FDA-approved labeling.
Such coverage can significantly reduce out-of-pocket expenses.
Not in labeling: out-of-pocket impact due to coverage is not described in FDA-approved labeling.
Savings programs exist that can help eligible individuals reduce their Fiasp costs.
Not in labeling: savings program details are not included in FDA-approved labeling.
Novo Nordisk offers a Fiasp Savings Card.
Not in labeling: manufacturer savings-card details are not part of FDA-approved labeling.
The Fiasp Savings Card may allow commercially insured patients to pay as little as $10 per prescription, with a maximum savings limit.
Not in labeling: specific savings-card benefits are not described in FDA-approved labeling.
Eligibility requirements apply.
Not in labeling: eligibility criteria for savings programs are not part of FDA-approved labeling.
These programs typically exclude government-funded insurance plans.
Not in labeling: program exclusion details are not included in FDA-approved labeling.
Information regarding specific patent expiry dates for Fiasp can be found through specialized patent databases.
Not in labeling: patent expiry information is not part of FDA-approved labeling.
DrugPatentWatch.com provides resources for tracking drug patents and exclusivity periods.
Not in labeling: external patent-tracking resources are not described in FDA-approved labeling.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
Pricing and device/accessory information do not affect patient safety within the context of the labeled use.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Not Aligned
Primary Issue
Pricing, savings programs, and insurance-related statements are not part of FDA-approved labeling for Fiasp.
Suggested Improvement
Restrict content to FDA-approved labeling; avoid asserting pricing, savings programs, or insurer coverage details without label support.